Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a record €8 billion in 2024, it said today. Fuelled by ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

A pair of properly fitting running shoes will feel better on your feet and help you run more comfortably than a pair of shoes that fit poorly or are worn past their expiration date, according to ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...

In a few weeks, we will carry this mission forward while maintaining the authority, depth and intelligence we always aspire to. At the same time we will introduce significant changes to the way in ...

Pre-Market: 7:10:04 a.m. EDT ...